Intra-Cellular Therapies Inc. (ITCI) Financials
Stock symbol ITCI is outdated, potentially delisted? Maybe it is available on other exchange?
ITCI Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Dec. 31, 2024 | 1.4 billion | 218.5 million |
| Sept. 30, 2024 | 1.3 billion | 179.6 million |
| June 30, 2024 | 1.3 billion | 175.9 million |
| March 31, 2024 | 747.0 million | 147.5 million |
ITCI Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Dec. 31, 2024 | -12.7 million | 16.3 million |
| Sept. 30, 2024 | -27.2 million | 17.5 million |
| June 30, 2024 | 489000 | 16.4 million |
| March 31, 2024 | -34.1 million | 13.8 million |
ITCI Net Income
No data available :(
ITCI Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Dec. 31, 2024 | 1.0 billion | 12.7 million | 17.0 million |
| Sept. 30, 2024 | 1.0 billion | 13.5 million | 17.7 million |
| June 30, 2024 | 1.0 billion | 14.1 million | 18.3 million |
| March 31, 2024 | 477.4 million | 12.7 million | 16.4 million |
ITCI Shares Outstanding
ITCI Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Dec. 31, 2024 | 427000 | 70.3 million | 137.7 million | - |
| Sept. 30, 2024 | 696000 | 66.8 million | 132.1 million | - |
| June 30, 2024 | 53000 | 56.2 million | 121.6 million | - |
| March 31, 2024 | - | 42.8 million | 113.1 million | - |
ITCI Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Dec. 31, 2024 | 199.2 million | 20.4 million |
| Sept. 30, 2024 | 175.2 million | 15.3 million |
| June 30, 2024 | 161.4 million | 11.4 million |
| March 31, 2024 | 144.9 million | 9.9 million |
ITCI Revenue by Segment
Graph available only for paid members. Upgrade to see it.
ITCI
Price: $131.87
52 week price:
Earnings Per Share: -0.73 USD
P/E Ratio: -180.64
Exchange: NMS
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Volume: 307914
Ebitda: -22.8 millionMarket Capitalization: 14.0 billion